Search details
1.
Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B.
Hepatology
; 77(1): 275-289, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35699669
2.
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.
J Antimicrob Chemother
; 77(4): 1102-1110, 2022 03 31.
Article
in English
| MEDLINE | ID: mdl-35040959
3.
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Gastroenterology
; 159(2): 521-533.e9, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32343960
4.
Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy.
J Viral Hepat
; 27(11): 1127-1137, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32579776
5.
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
J Infect Dis
; 219(2): 177-185, 2019 01 07.
Article
in English
| MEDLINE | ID: mdl-30053042
6.
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Clin Pharmacol Drug Dev
; 11(12): 1419-1429, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36062869
7.
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Antivir Ther
; 26(1-2): 13-24, 2021.
Article
in English
| MEDLINE | ID: mdl-35485346
8.
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Adv Ther
; 37(4): 1703, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-32133584
9.
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Adv Ther
; 36(9): 2450-2462, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31267367
10.
Pharmacological preconditioning with hyperbaric oxygen: can this therapy attenuate myocardial ischemic reperfusion injury and induce myocardial protection via nitric oxide?
J Surg Res
; 149(1): 155-64, 2008 Sep.
Article
in English
| MEDLINE | ID: mdl-17996900
11.
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Antivir Ther
; 23(7): 555-566, 2018.
Article
in English
| MEDLINE | ID: mdl-29927386
12.
Can hyperbaric oxygen be used as adjunctive heart failure therapy through the induction of endogenous heat shock proteins?
Adv Ther
; 24(1): 106-18, 2007.
Article
in English
| MEDLINE | ID: mdl-17526467
13.
Hyperbaric oxygen: a novel technology for modulating myocardial schemia-reperfusion via a single drug.
Adv Ther
; 23(4): 528-33, 2006.
Article
in English
| MEDLINE | ID: mdl-17050495
14.
Hyperbaric oxygen: a new drug in myocardial revascularization and protection?
Cardiovasc Revasc Med
; 7(3): 146-54, 2006.
Article
in English
| MEDLINE | ID: mdl-16945821
15.
Hyperbaric oxygen preconditioning improves myocardial function, reduces length of intensive care stay, and limits complications post coronary artery bypass graft surgery.
Cardiovasc Revasc Med
; 11(1): 8-19, 2010.
Article
in English
| MEDLINE | ID: mdl-20129356
Results
1 -
15
de 15
1
Next >
>>